The hepatic expression level of cannabinoid receptor 1 (CB1), the target of anti-obesity drug rimonabant [21] can also be induced by the treatment of RA via activation of RAR-γ [22], indicating the connection between the nutritional signals and endocannabinoid pathways. This evidence concerns the gene CNR1 and obesity disorder.